Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$52.95
$0.14(0.27%)
At close: 4:00 PM EDT
$52.95
$0.14(0.27%)
Day’s Range― - ―
52-Week Range$14.79 - $62.32
Previous Close$53
Volume368.77K
Average Volume (3M)1.68M
Market Cap
$4.40B
Enterprise Value$2.46K
Total Cash (Recent Filing)$895.15M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 18, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding73,270,760
10 Day Avg. Volume622,646
30 Day Avg. Volume1,683,908
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.55Price Target Upside37.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity / Multi-year RunwayNearly $895M of cash and marketable securities provides multi-year runway into 2030, materially reducing near-term financing pressure. This liquidity supports pivotal ENABLE-2 initiation and ongoing R&D spending, allowing clinical execution over multiple years before product revenue is required.
Positive Clinical Data And FDA AlignmentUpdated Phase 1 efficacy/safety and explicit FDA agreement on the 80 mg Phase 3 dose and 2L+ enrollment materially de-risks development. Regulatory alignment and robust early efficacy position ELVN-001 to progress rapidly through pivotal stages and strengthens long-term commercialization prospects.
Raised Capital And Expanded Financing FlexibilityThe sizable upsized equity raise significantly bolsters the balance sheet and, combined with expanded authorized shares, increases strategic optionality to fund pivotal trials, partnerships, or business development without immediate operational cutbacks, supporting sustained pipeline investment.
Bears Say
Pre-commercial Status: No RevenueAs a clinical-stage biotech with zero product revenue, Enliven depends entirely on external financing or partnerships to fund operations. Persistent absence of revenues means long-term value creation hinges on successful clinical outcomes and approvals, increasing fundamental execution risk.
Sustained Negative Cash GenerationOperating and free cash flows remain materially negative, indicating R&D and operations consume cash each year. Even with improved burn versus prior year, continued negative cash generation necessitates future financings or collaborations, limiting financial flexibility if milestones are delayed.
Dilution Risk From Share Increases And OfferingsDoubling authorized shares and executing an upsized equity offering create clear capacity and precedent for further dilution. While this enables funding, repeated or large issuances can dilute existing holders and reflect reliance on equity markets rather than internal cash generation, a structural investor risk.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $62.32 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $4.40B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 90 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on Aug 05, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.387 by -$0.103.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.43.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 73,270,760 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.387. Following the earnings report the stock price went up 0.955%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.55 (37.01% Upside)
$72.55 (37.01% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 75%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $51.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 16.5%
Last 30 Days ▼ 16.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
80.64%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$72.55
▲(37.01% Upside)
Technical Analysis
Crispr Therapeutics AG
―
IDEAYA Biosciences
―
Legend Biotech
―
Relay Therapeutics
―
Tango Therapeutics
―
Ownership Overview
22.52% Insiders
13.90% Mutual Funds
8.00% Other Institutional Investors
46.03% Public Companies and
Individual Investors